GlassScriptPhysician profile
Faraaz A Rahman
NPI 1417249970
$22,143.27
in general payments reported to CMS, 2019-2025
26 companies · $2,351 in 2025
The $2,351 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,378 · 2020: $1,861 · 2021: $1,831 · 2022: $1,170 · 2023: $1,144 · 2024: $7,408 · 2025: $2,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,008 · Food and Beverage: $4,895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,008.45 |
| Food and Beverage | $4,894.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,005.67 | 2019-2025 | Triclip, Mitraclip, Diamondback Coronary |
| Edwards Lifesciences Corporation | $4,892.56 | 2019-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Pascal |
| Medtronic Vascular, INC. | $3,997.99 | 2019-2020 | |
| Medtronic, INC. | $3,170.93 | 2021-2024 | Corevalve Evolut R, Onyx Frontier, Harmony |
| Boston Scientific Corporation | $1,619.55 | 2019-2025 | Ekosonic, General - Molecular Intervention, Watchman Flx |
| W. L. Gore & Associates, INC. | $1,223.81 | 2024 | Gore Cardioform Septal Occluder |
| Terumo Medical Corporation | $526.28 | 2021-2024 | Glidesheath Slender, Glidewire, Angio-Seal |
| Baylis Medical Company INC | $352.30 | 2019 | |
| Novartis Pharmaceuticals Corporation | $209.82 | 2022-2025 | |
| Abiomed | $189.85 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $154.68 | 2020-2024 | Lifevest |
| Pfizer INC. | $118.48 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $105.13 | 2021-2022 | |
| Amgen INC. | $95.77 | 2021-2024 | Repatha |
| Chiesi USA, INC. | $86.06 | 2021-2025 | Kengreal, Cleviprex |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $75.42 | 2023-2024 | Opsumit, Uptravi |
| Cardiovascular Systems INC. | $74.07 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $44.79 | 2021-2024 | Farxiga |
| Teleflex LLC | $34.30 | 2021-2024 | Spectre |
| Zoll Circulation INC | $29.87 | 2021 | |
| Cvrx, INC. | $25.60 | 2022 | |
| Argon Medical Devices, INC. | $24.60 | 2025 | Clot Management |
| Silk Road Medical, INC. | $23.86 | 2022 | |
| Heartflow, INC. | $21.87 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $21.46 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faraaz Rahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.